The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Impact of sustained MRD negativity on outcomes in transplant-eligible newly diagnosed myeloma
Mattia D’Agostino, MD, University of Turin, Turin, Italy, discusses the impact of sustained measurable residual disease (MRD) negativity on long-term outcomes in transplant-eligible patients with newly diagnosed multiple myeloma (MM) enrolled in the Phase II FORTE trial (NCT02203643). Dr D’Agostino notes that sustained MRD negativity for more than three years significantly improved long-term progression-free survival (PFS) and overall survival (OS) rates, including among patients with high-risk disease at baseline. Among patients who achieved at least five years of sustained MRD negativity, the 7-year PFS was encouraging at 91%. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
